Gemzar Narrow Progression-Free Survival Benefit To Test Oncology Panel's Efficacy Bar
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Oncologic Drugs Advisory Committee will review Lilly's gemcitabine for treatment of advanced ovarian cancer March 13.